# Chapter 22: Regulatory Science

## 22.1 Overview
BioDockify supports regulatory submissions through QSAR validation, read-across, and compliance documentation.

---

## 22.2 FDA IND/NDA Support

### IND Filing
- QSAR predictions for ADMET properties
- Toxicity alerts (hERG, AMES)
- Drug-likeness assessment
- Pharmacokinetic predictions

### NDA Filing
- Full ADMET profile (SwissADME 6-section)
- Binding affinity data (docking scores)
- Statistical analysis of efficacy data
- Literature review with citations

---

## 22.3 EMA MAA Documentation
- Similar to FDA requirements
- Additional focus on:
  - Environmental risk assessment
  - Pediatric considerations
  - Pharmacovigilance planning

---

## 22.4 ICH Guidelines

| Guideline | Topic | BioDockify Support |
|-----------|-------|-------------------|
| ICH E9 | Statistical principles | Statistics suite (20 tests) |
| ICH M3 | Non-clinical safety | hERG, AMES, toxicity filters |
| ICH S6 | Biotechnology products | N/A (small molecules only) |

---

## 22.5 QSAR for Regulatory Acceptance

### OECD 5 Principles
1. **Defined endpoint** — Activity/property being predicted
2. **Unambiguous algorithm** — Model type and parameters documented
3. **Defined domain** — Applicability domain via Williams Plot
4. **Measures of goodness-of-fit** — R², Q², RMSE, MCC
5. **Mechanistic interpretation** — Feature importance, interaction analysis

---

## 22.6 Read-Across for Data Gap Filling
1. Identify target compound without experimental data
2. Find structural analogues in training set
3. Use QSAR prediction + read-across confidence
4. Document similarity metrics (Tanimoto)
5. Provide uncertainty estimates

---

## 22.7 Bioequivalence (TOST)
- Two One-Sided Tests for generic drug approval
- 90% confidence interval for AUC ratio
- Acceptance criteria: 80-125%

---

## 22.8 Power Analysis
- Sample size calculation for clinical trials
- Effect size estimation
- Significance level (α = 0.05)
- Power (1-β = 0.80)

---

## 22.9 Limitations
- QSAR predictions are not experimental data
- Should be used as weight-of-evidence, not standalone
- Regulatory acceptance varies by jurisdiction
- Always validate with experimental studies
